GENERALI, DANIELE
GENERALI, DANIELE
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer
2015 Generali, Daniele; Venturini, Sergio; Rognoni, Carla; Ciani, Oriana; Pusztai, Lajos; Loi, Sherene; Jerusalem, Guy; Bottini, Alberto; Tarricone, Rosanna
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
2015 Bazzola, Letizia; Foroni, Chiara; Andreis, Daniele; Zanoni, Vanessa; R. Cappelletti, Mariarosa Rosa; Allevi, Giovanni; Aguggini, Sergio; Strina, Carla; Milani, Manuela; Venturini, Sergio; Ferrozzi, Francesco; Giardini, Roberto; Bertoni, Ramona; Turley, Helen; Gatter, Kevin C; Petronini, Piergiorgio; Fox, Stephen B; Harris, Adrian L.; Martinotti, Mario; Berruti, Alfredo; Bottini, Alberto; Reynolds, Andrew R.; Generali, Daniele
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment
2014 Generali, D.; Buffa, F. M.; Deb, S.; Cummings, M.; Reid, L. E.; Taylor, M.; Andreis, D.; Allevi, G.; Ferrero, G.; Byrne, D.; Martinotti, M.; Bottini, A.; Harris, A. L.; Lakhani, S. R.; Fox, S. B.
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/HER2‐negative metastatic breast cancer: systematic review and meta‐analysis
2021 Schettini, Francesco; Giuliano, Mario; Giudici, Fabiola; Conte, Benedetta; De Placido, Pietro; Venturini, Sergio; Rognoni, Carla; Di Leo, Angelo; Locci, Mariavittoria; Jerusalem, Guy; Del Mastro, Lucia; Puglisi, Fabio; Conte, Pierfranco; De Laurentiis, Michelino; Pusztai, Lajos; Rimawi, Mothaffar F.; Schiff, Rachel; Arpino, Grazia; De Placido, Sabino; Prat, Aleix; Generali, Daniele
New omics information for clinical trial utility in the primary setting
2011 Damia, Giovanna; Broggini, Massimo; Marsoni, Silvia; Venturini, Sergio; Generali, Daniele
Phosphorylated ER alpha, HIF-1 alpha, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer
2009 Generali, Daniele; Buffa, Francesca M.; Berruti, Alfredo; Brizzi, Maria P.; Campo, Leticia; Bonardi, Simone; Bersiga, Alessandra; Allevi, Giovanni; Milani, Manuela; Aguggini, Sergio; Papotti, Mauro; Dogliotti, Luigi; Bottini, Alberto; Harris, Adrian L.; Fox, and Stephen B.
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy"
2014 Foroni, Chiara; Milan, Manuela; Strina, Carla; Cappelletti, Mariarosa; Fumarola, Claudia; Bonelli, Mara; Bertoni, Ramona; Ferrero, Giuseppina; Maldotti, Mara; Takano, Elena; Andreis, Daniele; Venturini, Sergio; Brugnoli, Giulia; Petronini, Pier Giorgio; Zanoni, Vanessa; Pritzker, Laura; Pritzker, Kenneth; Parissenti, Amadeo; Santini, Daniele; Fox, Stephen B.; Bottini, Alberto; Generali, Daniele
Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: a meta-regression of randomised prospective studies
2017 Roviello, Giandomenico; Andre, Fabrice; Venturini, Sergio; Pistilli, Barbara; Curigliano, Giuseppe; Cristofanilli, Massimo; Rossellini, Pietro; Generali, Daniele
Role of targeted agents in neuroendocrine tumours: results from a meta-analysis
2016 Roviello, Giandomenico; Zanotti, Laura; Venturini, Sergio; Bottini, Alberto; Generali, Daniele
| Titolo | Data di pubblicazione | Autore(i) | Rivista | Editore |
|---|---|---|---|---|
| A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer | 1-gen-2015 | Generali, Daniele; Venturini, Sergio; Rognoni, Carla; Ciani, Oriana; Pusztai, Lajos; Loi, Sherene; Jerusalem, Guy; Bottini, Alberto; Tarricone, Rosanna | BREAST CANCER RESEARCH AND TREATMENT | - |
| Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer | 1-gen-2015 | Bazzola, Letizia; Foroni, Chiara; Andreis, Daniele; Zanoni, Vanessa; R. Cappelletti, Mariarosa Rosa; Allevi, Giovanni; Aguggini, Sergio; Strina, Carla; Milani, Manuela; Venturini, Sergio; Ferrozzi, Francesco; Giardini, Roberto; Bertoni, Ramona; Turley, Helen; Gatter, Kevin C; Petronini, Piergiorgio; Fox, Stephen B; Harris, Adrian L.; Martinotti, Mario; Berruti, Alfredo; Bottini, Alberto; Reynolds, Andrew R.; Generali, Daniele | BRITISH JOURNAL OF CANCER | - |
| COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment | 1-gen-2014 | Generali, D.; Buffa, F. M.; Deb, S.; Cummings, M.; Reid, L. E.; Taylor, M.; Andreis, D.; Allevi, G.; Ferrero, G.; Byrne, D.; Martinotti, M.; Bottini, A.; Harris, A. L.; Lakhani, S. R.; Fox, S. B. | BRITISH JOURNAL OF CANCER | - |
| Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/HER2‐negative metastatic breast cancer: systematic review and meta‐analysis | 1-gen-2021 | Schettini, Francesco; Giuliano, Mario; Giudici, Fabiola; Conte, Benedetta; De Placido, Pietro; Venturini, Sergio; Rognoni, Carla; Di Leo, Angelo; Locci, Mariavittoria; Jerusalem, Guy; Del Mastro, Lucia; Puglisi, Fabio; Conte, Pierfranco; De Laurentiis, Michelino; Pusztai, Lajos; Rimawi, Mothaffar F.; Schiff, Rachel; Arpino, Grazia; De Placido, Sabino; Prat, Aleix; Generali, Daniele | CANCERS | - |
| New omics information for clinical trial utility in the primary setting | 1-gen-2011 | Damia, Giovanna; Broggini, Massimo; Marsoni, Silvia; Venturini, Sergio; Generali, Daniele | JOURNAL OF THE NATIONAL CANCER INSTITUTE | - |
| Phosphorylated ER alpha, HIF-1 alpha, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer | 1-gen-2009 | Generali, Daniele; Buffa, Francesca M.; Berruti, Alfredo; Brizzi, Maria P.; Campo, Leticia; Bonardi, Simone; Bersiga, Alessandra; Allevi, Giovanni; Milani, Manuela; Aguggini, Sergio; Papotti, Mauro; Dogliotti, Luigi; Bottini, Alberto; Harris, Adrian L.; Fox, and Stephen B. | JOURNAL OF CLINICAL ONCOLOGY | - |
| Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy" | 1-gen-2014 | Foroni, Chiara; Milan, Manuela; Strina, Carla; Cappelletti, Mariarosa; Fumarola, Claudia; Bonelli, Mara; Bertoni, Ramona; Ferrero, Giuseppina; Maldotti, Mara; Takano, Elena; Andreis, Daniele; Venturini, Sergio; Brugnoli, Giulia; Petronini, Pier Giorgio; Zanoni, Vanessa; Pritzker, Laura; Pritzker, Kenneth; Parissenti, Amadeo; Santini, Daniele; Fox, Stephen B.; Bottini, Alberto; Generali, Daniele | BREAST CANCER RESEARCH AND TREATMENT | - |
| Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: a meta-regression of randomised prospective studies | 1-gen-2017 | Roviello, Giandomenico; Andre, Fabrice; Venturini, Sergio; Pistilli, Barbara; Curigliano, Giuseppe; Cristofanilli, Massimo; Rossellini, Pietro; Generali, Daniele | EUROPEAN JOURNAL OF CANCER | - |
| Role of targeted agents in neuroendocrine tumours: results from a meta-analysis | 1-gen-2016 | Roviello, Giandomenico; Zanotti, Laura; Venturini, Sergio; Bottini, Alberto; Generali, Daniele | CANCER BIOLOGY & THERAPY | - |